Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

20/20 GeneSystems Awarded $750,000 NCI Contract

Published: Wednesday, February 26, 2014
Last Updated: Wednesday, February 26, 2014
Bookmark and Share
Award will see 20/20 develop companion diagnostic for targeted therapies in kidney cancer.

20/20 GeneSystems, Inc. announces that the NCI has awarded the company a cost-sharing Phase II Small Business Innovation and Research (SBIR) contract to develop, optimize, and validate (analytically and clinically) a test to help predict whether a patient with advanced stage kidney cancer (renal cell carcinoma) is likely to benefit from anti-angiogenic therapy. The anticipated end result is a diagnostic test that will indicate to oncologists the appropriate treatment for patients. 

With an estimated 65,000 new cases in the US in 2013 kidney cancer represents 3% of all cancers yet the disease is the 6th leading cancer death, with an estimated 13,600 deaths in 2013. Kidney cancer does not exhibit any symptoms at an early stage it therefore often remains undetected until it is advanced. Advanced renal cell carcinoma does not respond to chemotherapy and radiation. Three types of treatments are currently used: immunotherapy, anti-angiogenic agents, and mTOR inhibitors and no treatment is effective in more than a fraction of patients. Kidney cancer can progress very rapidly. Once the cancer is detected it is important to select the right treatment as quickly as possible. 

“There is a large unmet clinical need for an assay to identify kidney cancer patients likely to respond or not respond to a particular therapy. The early results which 20/20 presented last year are very promising. The 20/20 test would help guide treatment decisions and strategies so we can provide the best informed care to our patients,” says Sandy Srinivas, MD, Associate Professor of Oncology at the Stanford University School of Medicine. “There is a definite need for a companion diagnostic to predict response to anti-angiogenic drugs as there are other targeted therapies, with other mechanisms of action, which may be more suitable”. 

The development of the proof of concept development was funded by Phase I SBIR contract HHSN261201000135C from the National Cancer Institute and private funds. 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!